Author + information
- Received September 30, 1991
- Revision received January 10, 1992
- Accepted February 18, 1992
- Published online July 1, 1992.
- Karl T. Weber, MD, FACC∗,a,
- Piero Anversa, MDb,
- Paul W. Armstrong, MD, FACCc,
- Christian G. Brilla, MD, PhDd,
- John C. Burnett Jr., MDe,
- John M. Cruickshank, MD, FRCPf,
- Richard B. Devereux, MD, FACCg,
- Thomas D. Giles, MD, FACCh,
- Niels Korsgaard, MDi,
- Carl V. Leier, MD, FACCj,
- Frederick A.O. Mendelsohn, MD, PhD, FRCPk,
- Wolfgang H. Motz, MDl,
- Michael J. Mulvany, PhDm and
- Bodo E. Strauer, MDn
- ↵∗Address for correspondence: Karl T. Weber, MD, University of Missouri—Columbia, School of Medicine, Department of Medicine, Division of Cardiology, MA432 Medical Science Building, 1 Hospital Drive, Columbia, Missouri 65212.
Growth or altered metabolism of nonmyocyte cells (cardiac fibroblasts, vascular smooth muscle and endothelial cells) alters myocardial and vascular structure (remodeling) and function. However, the precise roles of circulating and locally generated factors such as angiotensin II, aldosterone and endothelin that regulate growth and metabolism of nonmyocyte cells have yet to be fully elucidated. Trials of pharmacologic therapy aimed at preventing structural remodeling and repairing altered myocardial structure to or toward normal in the setting of hypertension, heart failure and diabetes are reviewed. It is proposed that these are therapeutic goals that may reduce cardiovascular morbidity and mortality. Although this hypothesis remains unproved the primary goal of therapy should be to preserve or restore tissue structure and function.
☆ The publication of this review article was derived from a meeting made possible by an educational grant from ICI Pharmaceuticals.
☆☆ The meeting on which this review is based was made possible under an educational grant from ICI Pharmaceutical. We acknowledge John H. Bauer, MD and Victor J. Dzau, MD for contributing to the symposium and Adelphi Communications for their editorial services.
- Received September 30, 1991.
- Revision received January 10, 1992.
- Accepted February 18, 1992.